Navigation Links
New Report 'Looking at Chiral Technologies' Analyzes the Global,Market Growth Forecasts Driven By Two Very Important Components as,Single Isomer Drugs and Single Enantiomer Pharmaceuticals

DUBLIN, Ireland--(BUSINESS WIRE)--Jun 21, 2007 - Research and Markets (http://www.researchandmarkets.com/reports/c60415) has announced the addition of Looking at Chiral Technologies to their offering.

The advancements in molecular research and continued untiring efforts of the research industry to develop better more precisely applicable Pharmaceuticals as well as agro compounds would have not been possible without the advent of Chiral technologies and their applications.

The usage of chiral molecules is at the very centre of this technological revolution when coupled with the application of chiral technologies as: Chiral Pool, Resolution, Biocatalysts, or asymmetric analysis creates the required compounds. The majority of development activity is routed through fine chemical companies which are additionally trying to upgrade their capabilities in order to provide to the entire portfolio of pharmaceutical drugs for application in the consumer arena.

Such ramping up of operations by companies in order to develop and upgrade basic molecules for wide ranging applications is also bringing the focus of chiral technologies into the development of clinical cures.

This report - Looking at Chiral Technologies - introduces the concept of Chiral Technologies supplementing it with its variants and explaining the actions undertaken by the industry towards developing such compounds jointly and deriving common benefits of clinical nature. The report also analyzes the global market growth forecasts driven by two very important components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals which are synthesized in bulk nature which are contributing to deriving drug streams worldwide.

The report explains the sales of Single Enantiomer pharma on a YOY basis, which is being controlled by certain regulatory constraints. The report also presents an insight on the synergies developed by the industr y majors by building long term partnerships as well as sustaining healthy competition which will lead to the development of the industry as a whole.

The market for Chiral Technologies has been demarcated by end user applications in this report further to which the report provides a future perspective on the industry outlook for Chiral Technologies.

Content Outline:

A. Executive Summary

B. Understanding the Chiral Concept

C. Industry Profile

D. Different Chiral Models for Flexible Markets

E. Intellectual Property Issues

F. Bringing the Molecule to a Commercial Scale - Issues & Challenges

G. How the Pharma Industry is Driving Chiral Technologies

H. Market Demarcations by Chiral Applications

I. Chiral Technology Industry - Future Perspective

J. Major Market Players

K. Appendix

L. Glossary of Terms

Companies Mentioned:

- Altus Biologics Inc

- Ascot Fine Chemicals

- Avecia

- Bachem

- Callery Chemical Company

- Cambrex Corporation

- Catalytica Inc

- Chemi SpA

- ChiRex

- ChromTech International

- Daicel Chemical Industries Ltd

- Daiso Company Ltd

- Degussa-Huls

- DSM

- Great Lakes Fine Chemicals

- IMI (TAMI)

- Johnson Matthey plc

- Kaneka Corporation

- Lonza Ltd

- Novasep

- Oxford Asymmetry International

- Pfanstiehl Laboratories

- PPG-Sipsy

- Sepracor Inc

- Solvias

- Synetix

- Synthon Chiragenics Corporation

For more information visit http://www.researchandmarkets.com/reports/c60415

Contact

Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax: +353 1 4100 980


'"/>




Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):